ArticleFrontiers in pain research (Lausanne, Switzerland)2026

Treatment characteristics and safety profiles of Belbuca®, buprenorphine patch, and oral schedule II opioids among chronic low back pain patients without a positive history of opioid-use disorder: a retrospective US commercial claims analysis.

Vladimir Zah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.